NDAORALTABLET
Approved
Jan 2011
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VIIBRYD (vilazodone hydrochloride) by AbbVie. Approved for post-traumatic stress disorder. First approved in 2011.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIIBRYD (vilazodone hydrochloride) is an oral tablet antidepressant approved by the FDA on January 21, 2011, for the treatment of major depressive disorder in adults. It is a selective serotonin reuptake inhibitor (SSRI) with 5-HT1A receptor partial agonist activity. The combination mechanism differentiates it within the SSRI class by potentially offering enhanced efficacy with improved tolerability, particularly regarding sexual dysfunction. It is marketed by AbbVie and represents a branded antidepressant option in a mature, highly competitive therapeutic category.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on VIIBRYD at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.